- Home
- DNMX vs ACHV Comparison
DNMX vs ACHV Comparison
Compare DNMX & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DNMX | ACHV |
|---|---|---|
| Founded | 2025 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 265.4M | 233.7M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | DNMX | ACHV |
|---|---|---|
| Price | $9.93 | $4.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.50 |
| AVG Volume (30 Days) | 52.6K | ★ 337.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 17.33 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.87 | $1.84 |
| 52 Week High | $9.99 | $6.03 |
Technical Indicators
Market Signals| Indicator | DNMX | ACHV |
|---|---|---|
| Relative Strength Index (RSI) | 50.42 | 44.30 |
| Support Level | $9.87 | $4.24 |
| Resistance Level | $9.99 | $4.30 |
| Average True Range (ATR) | 0.02 | 0.23 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 42.86 | 24.82 |
Price Performance
Historical ComparisonAbout DNMX Dynamix Corporation III Class A Ordinary Shares
Dynamix Corp III is a a blank check company incorporated as a Cayman Islands exempted company and incorporated for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.